海南元盈医药科技

Hainan Yuanying Pharmaceutical Technology is a China-based biotechnology company dedicated to the research and development of innovative small molecule drugs. The company primarily focuses on therapeutic areas such as immunology, inflammation, and oncology, aiming to address significant unmet clinical needs. Its core pipeline includes YY-001, a highly selective Janus kinase 1 (JAK1) inhibitor designed for the treatment of autoimmune and inflammatory conditions like atopic dermatitis. Based in the Hainan Free Trade Port, the firm utilizes local regulatory advantages to streamline its clinical development and commercialization strategies. Yuanying Pharmaceutical maintains a robust R&D infrastructure to support its drug discovery programs from early-stage research through clinical trials.